Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights - Slideshow

Autolus Therapeutics presented clinical updates on its CAR-T therapy for B-cell precursor acute lymphoblastic leukemia (ALL), highlighting Phase 1/2 trial progress during an April 2026 investor event. The company emphasized obe-cel’s potential as a first-in-class fast-off-rate CD19 CAR-T, designed to reduce severe cytokine release syndrome (CRS) while maintaining efficacy in relapsed/refractory ALL patients. Early data showed durable responses, with 85% complete remission rates in pediatric and young adult cohorts, though long-term follow-up remains ongoing for sustained efficacy validation. Safety profiles improved compared to traditional CAR-T therapies, with lower-grade CRS and neurotoxicity reported, aligning with obe-cel’s engineered fast-off-rate mechanism to minimize adverse events. Next steps include expanding trials to broader patient populations and pursuing regulatory discussions, aiming for accelerated approval pathways based on interim efficacy and safety results.